141 related articles for article (PubMed ID: 21790243)
21. Effects of Smoking on Cost of Hospitalization and Length of Stay among Patients with Lung Cancer in Iran: a Hospital-Based Study.
Sari AA; Rezaei S; Arab M; Majdzadeh R; Matin BK; Zandian H
Asian Pac J Cancer Prev; 2016; 17(9):4421-4426. PubMed ID: 27797255
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of state costs of the social security benefits provided to the insured presenting with lung cancer and pulmonary diseases caused by external factors].
Kuklińska-Janiak D
Pol Merkur Lekarski; 2013 Dec; 35(210):339-46. PubMed ID: 24490462
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
24. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
26. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
27. Second-line and third-line chemotherapy for lung cancer: use and cost.
Ramsey SD; Martins RG; Blough DK; Tock LS; Lubeck D; Reyes CM
Am J Manag Care; 2008 May; 14(5):297-306. PubMed ID: 18471034
[TBL] [Abstract][Full Text] [Related]
28. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Michaud K; Messer J; Choi HK; Wolfe F
Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Hospice Care on Survival and Healthcare Costs for Patients with Lung Cancer: A National Longitudinal Population-Based Study in Taiwan.
Chiang JK; Kao YH; Lai NS
PLoS One; 2015; 10(9):e0138773. PubMed ID: 26406871
[TBL] [Abstract][Full Text] [Related]
30. The economics of lung cancer management in Canada.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
[TBL] [Abstract][Full Text] [Related]
31. Socioeconomic costs of open surgery and gamma knife radiosurgery for benign cranial base tumors.
Cho DY; Tsao M; Lee WY; Chang CS
Neurosurgery; 2006 May; 58(5):866-73; discussion 866-73. PubMed ID: 16639320
[TBL] [Abstract][Full Text] [Related]
32. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
33. The economic burden of brain metastasis among lung cancer patients in the United States.
Guérin A; Sasane M; Dea K; Zhang J; Culver K; Nitulescu R; Wu EQ; Macalalad AR
J Med Econ; 2016; 19(5):526-36. PubMed ID: 26735844
[TBL] [Abstract][Full Text] [Related]
34. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland.
Delcò F; Egger R; Bauerfeind P; Beglinger C
Aliment Pharmacol Ther; 2005 Mar; 21(5):615-22. PubMed ID: 15740546
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers.
Porter GA; Cantor SB; Walsh GL; Rusch VW; Leung DH; DeJesus AY; Pollock RE; Brennan MF; Pisters PW
J Thorac Cardiovasc Surg; 2004 May; 127(5):1366-72. PubMed ID: 15115994
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
37. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
38. Evaluating Direct Costs of Gastric Cancer Treatment in Iran - Case Study in Kerman City in 2015.
Izadi A; Sirizi MJ; Esmaeelpour S; Barouni M
Asian Pac J Cancer Prev; 2016; 17(6):3007-13. PubMed ID: 27356726
[TBL] [Abstract][Full Text] [Related]
39. Observations in lung cancer over multiple decades: an analysis of outcomes and cost at a single high-volume institution.
Lanuti M; Hong HJ; Ali S; Stock C; Temel J; Mathisen D; Michaelson JS
Eur J Cardiothorac Surg; 2014 Aug; 46(2):254-61; discussion 261. PubMed ID: 24453265
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
